Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study

Background: Body weight (BW) loss is an essential therapeutic goal in type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists are effective in reducing BW, but their effect on body composition has not yet been fully explored. The study aim was to assess the impact of Semaglutide on body com...

Descripción completa

Detalles Bibliográficos
Autores principales: Volpe, Sara, Lisco, Giuseppe, Racaniello, Davide, Fanelli, Margherita, Colaianni, Valentina, Vozza, Alfredo, Triggiani, Vincenzo, Sabbà, Carlo, Tortorella, Cosimo, De Pergola, Giovanni, Piazzolla, Giuseppina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227575/
https://www.ncbi.nlm.nih.gov/pubmed/35745144
http://dx.doi.org/10.3390/nu14122414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227575/
https://www.ncbi.nlm.nih.gov/pubmed/35745144
http://dx.doi.org/10.3390/nu14122414

Ejemplares similares